A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients
Table 4
Mean changes from baseline for the QoL scales of the EORTC QLQ-C30.
EORTC QLQ-C30 scale
Estimated changes*
95% CI
-value
Physical functioning
Viscum
7.30
[0.15; 14.44]
0.046
Etoposide
−2.45
[−8.93; 4.03]
0.430
Role functioning
Viscum
3.80
[−7.94; 15.54]
0.827
Etoposide
−6.31
[−18.28; 5.65]
0.508
Emotional functioning
Viscum
−5.98
[−10.58; −1.37]
0.014
Etoposide
−2.48
[−9.84; 4.87]
0.481
Cognitive functioning
Viscum
−0.92
[−6.49; 4.65]
0.734
Etoposide
−5.94
[−12.19; 0.31]
0.061
Social functioning
Viscum
11.76
[4.64; 18.88]
0.003
Etoposide
4.78
[0.51; 9.05]
0.031
Global health/QoL
Viscum
11.17
[2.62; 19.72]
0.013
Etoposide
3.51
[−3.51; 10.54]
0.301
Fatigue
Viscum
−9.85
[−16.31; −3.38]
0.005
Etoposide
1.13
[−5.72; 7.99]
0.73
Nausea/vomiting
Viscum
0.43
[−2.70; 3.56]
0.779
Etoposide
5.47
[0.28; 10.66]
0.040
Pain
Viscum
−10.71
[−18.83; −2.60]
0.012
Etoposide
10.54
[4.64; 16.45]
0.002
Dyspnoea
Viscum
−12.63
[−16.94; −8.32]
<0.0001
Etoposide
5.82
[−1.04; 12.68]
0.090
Insomnia
Viscum
−11.35
[−20.74; −1.96]
0.020
Etoposide
5.79
[−2.95; 14.53]
0.177
Appetite loss
Viscum
−6.40
[−6.40; −6.40]
N.E.†
Etoposide
1.41
[−2.15; 4.96]
0.410
Constipation
Viscum
−5.54
[−13.58; 2.50]
0.166
Etoposide
−0.62
[−9.65; 8.41]
0.884
Diarrhea
Viscum
0.83
[−2.81; 4.47]
0.639
Etoposide
2.44
[−1.92; 6.80]
0.251
Financial problems
Viscum
−11.46
[−16.21; −6.70]
<0.0001
Etoposide
−2.53
[−6.88; 1.83]
0.234
Estimates resulting from a linear mixed model, including baseline score, treatment and visit as fixed factors, and patients as random factors. †All postbaseline values in the Viscum group were 0; therefore no test statistic could be calculated.
